National Influenza Vaccination Week: Observed from December 1-5, this campaign encourages vaccination against the flu, emphasizing its safety and effectiveness, and serves as a reminder that it's never too late to get vaccinated.
World AIDS Day: Celebrated on December 1, this global observance raises awareness about HIV/AIDS, honors those lost, and supports those living with the virus, with a focus on political leadership and human rights to end AIDS as a public health threat by 2030.
HIV Statistics: In 2024, approximately 40.8 million people were living with HIV, with around 630,000 deaths from HIV-related causes and 1.3 million new infections, highlighting the ongoing impact of the epidemic.
Funding Concerns: There are worries about significant cuts to international HIV funding, particularly from the U.S., which has historically contributed nearly 75% of global financing, with recent reductions affecting key commitments and activities related to World AIDS Day.
Wall Street analysts forecast INVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INVA is 37.33 USD with a low forecast of 31.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast INVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INVA is 37.33 USD with a low forecast of 31.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 19.740
Low
31.00
Averages
37.33
High
46.00
Current: 19.740
Low
31.00
Averages
37.33
High
46.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$45 -> $46
2025-12-16
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$45 -> $46
AI Analysis
2025-12-16
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Innoviva to $46 from $45 and keeps a Buy rating on the shares. The firm says zoliflodacin was approved on schedule.
Goldman Sachs
Sell
initiated
$17
2025-09-30
Reason
Goldman Sachs
Price Target
$17
2025-09-30
initiated
Sell
Reason
Goldman Sachs initiated coverage of Innoviva with a Sell rating and $17 price target. The stock's recent rally has raised the bar for the company's infectious disease platform platform going forward, the analyst tells investors in a research note. The firm believes Innoviva's 2031 royalty-related patent cliff will start to weigh on the stock's performance in 2026.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for INVA
Unlock Now
H.C. Wainwright
Raghuram Selvaraju
Buy
upgrade
$40 -> $45
2025-08-11
Reason
H.C. Wainwright
Raghuram Selvaraju
Price Target
$40 -> $45
2025-08-11
upgrade
Buy
Reason
H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Innoviva to $45 from $40 and keeps a Buy rating on the shares. The company's Q2 revenue and earnings outperformed expectations, the analyst tells investors in a research note.
Oppenheimer
Outperform
initiated
$35
2025-08-11
Reason
Oppenheimer
Price Target
$35
2025-08-11
initiated
Outperform
Reason
Oppenheimer initiated coverage of Innoviva with an Outperform rating and $35 price target. Innoviva is a holding company comprised of royalty distributions from Breo and Anoro, a specialty therapeutics unit with assets for treating acute critical care, and a strategic finance equity investments arm, the analyst tells investors in a research note. The firm believes the company's specialty therapeutics and royalty commercial results will drive share outperformance.
About INVA
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
